MedPath

Remote Ischemic Conditioning to Enhance Resuscitation (RICE) Pilot

Phase 1
Conditions
Cardiac Arrest
Interventions
Device: Active Remote Ischemic Conditioning
Device: Sham Remote Ischemic Conditioning
Registration Number
NCT04265807
Lead Sponsor
University of Washington
Brief Summary

Following resuscitation from out-of-hospital cardiac arrest (OHCA), reperfusion injury can cause cell damage in the heart and brain. Remote ischemic conditioning (RIC) consists of intermittent application of a device such as a blood pressure cuff to a limb to induce non-lethal ischemia. Studies in animals with cardiac arrest as well as in humans with acute myocardial infarction suggest that RIC before or after restoration of blood flow may reduce injury to the heart and improve outcomes but this has not been proven in humans who have had OHCA. The RICE pilot study is a single-center study to assess the feasibility of application of RIC in the emergency department setting for patients transported to the hospital after resuscitation from OHCA.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention GroupActive Remote Ischemic ConditioningA standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on an upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
Control GroupSham Remote Ischemic ConditioningThe control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
Primary Outcome Measures
NameTimeMethod
Attrition30 minutes from initiation of study intervention

Attrition assessed as the proportion of randomized subjects who do not remain on allocated therapy for the intended study duration among subjects randomly allocated. On therapy for the intended study duration consists of completing three cycles of inflation-deflation.

Secondary Outcome Measures
NameTimeMethod
Withdrawal of CareDischarge or 30 days after index arrest

assessed as the reduction of support (i.e. reducing pressors, lab draws or medications) or withdrawal of support (i.e. extubation, stopping drips/meds, changing to comfort care only) during hospitalization.

Hospital Free SurvivalWithin 30 days of index arrest

Hospital Free Survival (HFS) assessed as number of days alive and permanently out of hospital up to 30 days post arrest

Treatment Success30 minutes from initiation of study intervention

Treatment Success assessed as the proportion of intervention group patients who remain alive and on their allocated therapy for the intended study duration.

Cardiogenic ShockWithin 48 hours of index arrest

Cardiogenic Shock assessed as systolic BP \< 80 mmHg during any 6 h period within 48 h of the index arrest not due to a correctable cause, and treated with pressors or inotropes or placement of a mechanical cardiac assist device (e.g. intra-aortic balloon pump). Cardiogenic shock correlates with survival after resuscitation from cardiac arrest.

Myocardial InjuryWithin 24 hours of index arrest

Myocardial Injury assessed as peak serum troponin in ng/mL at any time point within 24 h of index arrest.

Renal DysfunctionWithin 24 hours of index arrest

Renal Dysfunction assessed using Risk, Injury, Failure, Loss, End Stage criteria.

Cardiac FunctionWithin 48 hours of index arrest

Cardiac Function assessed as left ventricular ejection fraction (LVEF) using echocardiograms ordered for clinical indications.

STEMIWithin 48 hours of index arrest

STEMI assessed as the presence of electrocardiographic (ECG) and biomarker criteria for acute myocardial infarction within 48 h of the index arrest. Note that ST-elevation on the first 12-lead ECG after resuscitation is a poor predictor of acute infarction in this population. These patients often develop infarctions during the subsequent 48 h.

Survival to DischargeDicharge or 30 days after index arrest

Survival to Discharge assessed as alive when discharged from hospital to home, nursing facility or rehabilitation. Patients transferred to another acute care facility (e.g. to undergo implantable defibrillator placement) will be considered still hospitalized.

Favourable Neurologic Status at DischargeDischarge or 30 days after index arrest

Favourable Neurologic Status at Discharge assessed using modified Rankin Score (MRS) \< 3 at hospital discharge or 30 days after index arrest.

Clinical Instability at DischargeDischarge or 30 days after index arrest

Clinical Instability at Discharge assessed using the Kosecoff Index measured at discharge based on the presence of nine symptoms and signs associated with increased risk of rehospitalization. Instability will be the presence of any of these.

Survival to 30 days after arrest30 days after index arrest

Survival to 30 Days After Cardiac Arrest assessed as alive 30 days after the index cardiac arrest as confirmed by a brief telephone interview.

AccrualThrough study completion, an average of 6 mos.

Accrual is the proportion of eligible subjects who have the study device applied

Trial Locations

Locations (1)

Graham Nichol

🇺🇸

Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath